ProCE Banner Activity


Recent Therapeutic Advances in Advanced SCLC

Text Module

In this module, Dr Carl M. Gay reviews what’s on the horizon for extensive-stage SCLC, including novel biomarker-driven therapies that promise to transform management of this hard-to-treat disease and research efforts to define therapeutic SCLC subtypes.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 26, 2024

Expiration: March 25, 2025



Carl M. Gay

Carl M. Gay, MD, PhD

Assistant Professor
Department of Thoracic/Head & Neck Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Amgen and AstraZeneca Pharmaceuticals.


AstraZeneca Pharmaceuticals

Target Audience

This educational program is intended for thoracic oncologists, medical oncologists, radiation oncologists, and other lung cancer professionals caring for patients with SCLC.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for the treatment of small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the latest evidence on available and emerging therapeutics for ES-SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtype-driven therapeutic strategies

  • Incorporate new therapies in personalized ES-SCLC treatment plans considering recent evidence, guideline updates, patient needs, values, and preferences

  • Use best practices for diagnosis and management of treatment-related toxicity

  • Identify patients with SCLC for enrollment on clinical trials exploring innovative targeted therapies and immunotherapy combinations


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Carl M. Gay, MD, PhD

Assistant Professor
Department of Thoracic/Head & Neck Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Carl M. Gay, MD, PhD: consultant/advisor/speaker: Abdera, AstraZeneca, Catalyst, Daiichi Sankyo, G1 Therapeutics, Jazz Pharmaceuticals, Monte Rosa, ST Cube.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 26, 2024, through March 25, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 or better and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.